Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-15
    E.g., 2018-11-15

Articles

9185 items
11:02 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection In vitro and cell culture studies identified kanglemycin-based RNAP inhibitors that could help treat rifamycin-resistant bacterial infections. In silico screening of soil bacteria genomes for gene clusters with homology to the rifamycin antibiotic-biosynthesis...
11:02 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction Mouse studies suggest inhibiting microglial activation could help treat obesity-associated cognitive dysfunction. In hippocampal tissue from a mouse model of obesity-associated cognitive dysfunction, microglia activation scores were higher than in normal mice. Also...
11:01 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Seizures Fruit fly studies suggest inhibiting FAK, integrin β, TLN1, TNS1 or MMP1 could help treat seizures. In a Drosophila model of mechanically induced seizures, an astrocyte-specific RNAi screen identified four genes encoding components of...
11:01 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Epilepsy Patient sample and mouse studies suggest agonizing FFAR1 could help treat temporal lobe epilepsy. In postmortem brain tissue samples from patients with temporal lobe epilepsy, neocortical levels of FFAR1 protein were higher than in...
11:00 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Autoimmune disease

INDICATION: Inflammatory bowel disease (IBD) In vitro and mouse studies identified an isopropylcarboxamide-based Hsp90B1 inhibitor that could help treat ulcerative colitis (UC). Structure-based design, chemical synthesis and in vitro activity and binding assays of isopropylcarboxamide analogs...
11:00 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Neurology Sheep studies suggest CLN5 gene therapy could help treat Batten disease, a genetic neurodegenerative disorder caused by mutations in CLN5 or 12 other genes. In a CLN5-deficient sheep model of Batten disease, intracerebroventricular plus...
11:00 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Patient sample and mouse studies suggest inhibiting miR-27a could help treat tuberculosis (TB). In peripheral blood mononuclear cells (PBMCs) from patients with active pulmonary TB, levels of miR-27a were higher than in PBMCs from...
10:59 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Mouse studies suggest nitric oxide precursors could help treat castration-resistant prostate cancer (CRPC). In a xenograft mouse model of CRPC, the endogenous NO precursor S-nitrosoglutathione decreased tumor growth, tumor cell proliferation and markers...
10:59 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Huntington’s disease (HD) Cell culture and fruit fly studies suggest promoting USP12 expression could help treat HD. In rat primary neurons expressing an HD-related mutant HTT fragment and induced pluripotent stem (iPS) cell-derived neurons...
10:58 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Pain Rat studies suggest promoting the expression of TRESK or inhibiting its negative regulators VEGF and VEGFR2 could help treat pain associated with bone metastasis. In a rat model of bone metastasis-associated pain, TRESK...

Pages